MetaVia has started higher-dose testing for DA-1726 in obesity. Read what this means for tolerability, competition, and the next clinical milestone.
Merck’s enlicitide decanoate beat oral rivals in Phase 3. Read what this could change for cholesterol care, PCSK9 adoption, and market strategy.
Can Merck turn WINREVAIR’s CADENCE data into a new treatment path in CpcPH-HFpEF? Read the full analysis of what changes next.
Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.